Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Pyogenic arthritis, pyoderma gangrenosum, and acne × MORAb-202 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Adenocarcinoma 2 Triple Negative Breast Neoplasms 1 Pyogenic arthritis, pyoderma gangrenosum, and acne 1 Ovarian Neoplasms 1 Neoplasms 1 Endometrial Neoplasms 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03386942 2022-11-28

A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

Eisai Inc.

Phase 1 Completed

Pyogenic arthritis, pyoderma gangrenosum, and acne, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡